Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data InflaRx N.V. files with the SEC in its annual reports.
In EUR millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2017
FY2018
FY2019
FY2020
FY2022
FY2022
FY2023
FY2024
FY2025
Revenue
0.06
0.17
0.03
Cost of revenue
0.53
3.32
7.27
Gross profit
-7.12
-19.6
-37.8
-0.47
-3.15
-7.24
Research and development
5.28
14.4
25
44.6
25.7
35.7
37.5
41
35.4
25.7
Selling, general and administrative
1.84
5.14
12.8
12.5
8.47
0.11
0.1
0.1
0.04
0.02
Selling and marketing
1
1.6
Operating income
-47.6
-32.2
-44.9
Interest expense
2.05
4.92
0
-0.02
0.03
0.02
0.05
0.04
0.02
0.04
Interest income
0
0.13
2.18
2.84
0.89
0.11
0.61
3.8
3.2
1.85
Pre-tax income
-8.94
-24.2
-29.8
-53.3
-34
-45.6
-29.5
-42.7
-46.1
-45.6
Income tax
0
0
0
0
0
0
0.01
0.01
Income from continuing operations
-6.89
-19.4
Net income
-8.94
-24.2
-29.8
-53.3
-34
-45.6
-29.5
-42.7
-46.1
-45.6
EPS, basic
-3.80
-2.58
-1.19
-2.05
-1.26
-1.10
-0.67
-0.78
-0.78
-0.68
EPS, diluted
-3.80
-2.58
-1.19
-2.05
-1.26
-1.10
-0.67
-0.78
-0.78
-0.68
Balance sheet
FY2017
FY2017
FY2018
FY2019
FY2020
FY2022
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
29.1
123
55.4
33.1
26
26.2
16.3
12.8
18.4
16
Inventory
11.4
6.9
Total current assets
29.4
124
158
119
86.3
95.7
97.4
109
71.7
53.6
Property, plant and equipment
0.17
0.62
0.58
0.41
0.27
0.33
0.29
0.26
0.29
Lease right-of-use assets
0.84
0.55
1.41
1.31
1.07
0.76
0.86
Intangible assets
0.01
0.04
0.22
0.45
0.35
0.24
0.14
Total assets
29.5
124
159
122
88.2
125
102
120
76
55.2
Accounts payable
1.53
4.47
6.66
12.4
8.26
8.57
4.99
12
11.4
5.4
Total current liabilities
1.75
4.77
7.76
14.1
10.1
18.8
13
16.8
14.2
13
Lease liabilities
0
0.33
0.22
1.07
0.99
0.75
0.4
0.64
Total liabilities
55.2
4.78
7.82
14.4
10.4
19.9
14.1
17.6
14.6
13.7
Paid-in capital
162
211
211
220
280
283
334
335
355
Retained earnings
-27.1
-51.3
-81.1
-134
-168
-214
-243
-286
-332
-378
Shareholders' equity
3.05
7.26
7.38
7.44
7.17
Total equity
-25.7
119
151
107
77.9
105
88.3
103
61.4
41.6
Total liabilities and equity
29.5
124
159
122
88.2
125
102
120
76
55.2
Cash flow statement
FY2017
FY2017
FY2018
FY2019
FY2020
FY2022
FY2022
FY2023
FY2024
FY2025
Net income
-8.94
-24.2
-29.8
-53.3
-34
-45.6
-29.5
-42.7
-46.1
-45.6
Cash from operations
-4.99
-12.2
-21.5
-43.2
-36.5
-39.9
-33.7
-37.8
-48.6
-35.3
Cash from investing
-0.05
-0.17
-99.4
20.3
21.4
-26
19.4
-17.7
52.4
3.23
Debt repaid
0
0
0.3
-0.37
-0.36
-0.36
-0.37
-0.39
-0.36
Stock issued
9.77
65.1
2.35
56.5
1.1
22.9
Cash from financing
30.9
109
49.6
-0.29
9.17
61.6
1.94
53
0.39
33.3
Exchange rate effect
0
-2.32
3.46
0.9
-1.17
4.59
2.46
-0.97
1.41
-3.59
Net change in cash
25.8
94.2
-71.4
-23.2
-5.99
-4.31
-12.4
-2.52
4.19
1.24
Interest paid
0.21
0
0
-0.02
0.03
0.02
0.04
0.04
0.02
0.03
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. No valuation: the share price is quoted in a different currency than the statements.
Profitability
Metric
Value
How it is calculated
Gross margin
-24,678.0%
Gross profit / revenue.
Pre-tax margin
-155,540.0%
Pre-tax income / revenue.
Net margin
-155,582.0%
Net income / revenue.
Operating cash flow margin
-120,399.0%
Cash from operations / revenue.
Return on equity (ROE)
-624.6%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-69.5%
Net income / average total assets.
R&D / revenue
87,691.0%
Research and development expense / revenue.
SG&A / revenue
54.4%
Selling, general and administrative expense / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-82.3%
Revenue vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
-3.6%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-0.4%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
-27.4%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-18.6%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-8.9%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
4.13x
Current assets / current liabilities.
Quick ratio
1.23x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
1.23x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-€0.68
Net income per basic share, as reported (split-adjusted).
What was InflaRx N.V.'s revenue in fiscal 2025?
InflaRx N.V. reported revenue of €29.3K for fiscal 2025, 82.3% lower than the year before.
Was InflaRx N.V. profitable in fiscal 2025?
No. It reported a net loss of €45.6M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.